DWP457

DWP457 is a long-acting insulin analog currently in preclinical development by Daewoong Pharmaceutical for the management of diabetes mellitus. Designed as a basal insulin, it aims to provide sustained glucose-lowering effects over an extended period, mimicking the natural basal insulin secretion of the pancreas. The drug functions by binding to and activating the insulin receptor, which facilitates glucose uptake into peripheral tissues like muscle and adipose cells and suppresses glucose production in the liver. Its long-acting profile is intended to offer stable glycemic control with a reduced risk of hypoglycemia and less frequent dosing compared to short-acting formulations.

Other names

Daewoong long-acting insulin